Open-Label Phase III Long-Term Safety Trial of Liprotamase
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm clinical study investigating the long-term safety of
ALTU-135 treatment in patients with cystic fibrosis (CF)-related exocrine pancreatic
insufficiency (PI).